The advent of induced pluripotent stem cells (iPSCs) marked a giant step forward towards the reality of converting one type of primary somatic cells into different lineages capable of clinically repairing damaged tissues and organs. However, the major drawbacks of iPSCs hinder their quick translation to the bedside. These drawbacks include the time-, cost-, and labor-intensive process in production of clinical products from iPSCs, and the inherent risk of long-term tumorigenesis due to the forced expression of transcription factors associated with pluripotency, which are often implicated as aberrations within the cancerous gene circuitry.